J and J Snack Foods Newswire

Comprehensive Real-Time News Feed for J and J Snack Foods.

Results 1 - 20 of 616 in J and J Snack Foods

  1. Anika Therapeutics' (ANIK) CEO Charles Sherwood on Q4 2014 Results - Earnings Call TranscriptRead the original story w/Photo

    9 hrs ago | Seeking Alpha

    Good day, ladies and gentlemen and welcome to the Anika Therapeutics' Fourth Quarter 2014 Earnings Conference Call. At this time, all participants are in a listen-only mode.

    Comment?

  2. South Carolina court orders Johnson amp; Johnson to pay $136 million in Risperdal caseRead the original story w/Photo

    19 hrs ago | Vallejo News

    South Carolina's Supreme Court ordered Johnson & Johnson to pay a penalty of $136 million, upholding a jury's finding that the drugmaker's Janssen unit had improperly marketed its anti-psychotic drug Risperdal and concealed its risks. A trial court had earlier ordered J&J to pay $327 million, but the Supreme Court more than halved that penalty, citing a provision in South Carolina law that no action can be taken in such cases after three years of the discovery of unlawful conduct.

    Comment?

  3. South Carolina court orders J&J to pay $136 mln in Risperdal caseRead the original story

    20 hrs ago | Reuters

    South Carolina's Supreme Court ordered Johnson & Johnson to pay a penalty of $136 million, upholding a jury's finding that the drugmaker's Janssen unit had improperly marketed its anti-psychotic drug Risperdal and concealed its risks. A trial court had earlier ordered J&J to pay $327 million, but the Supreme Court more than halved that penalty, citing a provision in South Carolina law that no action can be taken in such cases after three years of the discovery of unlawful conduct.

    Comment?

  4. Biotech Pharmacyclics Spikes On Buyout RumorsRead the original story w/Photo

    Wednesday | Investor's Business Daily

    Pharmacyclics stock was up 17%, above 220, in afternoon trading on the stock market today , continuing a recent run-up that has seen the stock rise more than 75% since Jan. 12. The Sunnyvale, Calif.-based company has a best-possible IBD Composite Rating of 99. With a market cap approaching $17 billion, Pharmacyclics wouldn't come cheap. Then again, the pharma industry hasn't exactly been shy about big buyouts lately, either.

    Comment?

  5. J&J wins Risperdal verdict cut, must pay South Carolina $136 millionRead the original story w/Photo

    Wednesday | The Item

    South Carolina's highest court cut a $327 million verdict against Johnson & Johnson by more than half while refusing to throw out a jury's finding that it deceptively marketed the antipsychotic drug Risperdal as safer than competing medicines. In a 4-1 ruling Wednesday, the Supreme Court cited a three- year limit on claims alleging Johnson & Johnson's Janssen unit violated South Carolina's Unfair Trade Practices Act.

    Comment?

  6. Why Pharmacyclics, Inc. Soared Higher TodayRead the original story w/Photo

    Wednesday | The Motley Fool

    So what: Pharmacyclics markets the cancer drug Imbruvica, and Imbruvica's sales have been climbing rapidly since its launch as a treatment for chronic lymphocytic leukemia last February. During the fourth quarter, sales of Imbruvica climbed from $142 million in the third quarter to $185 million.

    Comment?

  7. UPDATE 1-Pharmacyclics mulls sale; J&J, Novartis interested - BloombergRead the original story

    Wednesday | Reuters

    Cancer drug maker Pharmacyclics Inc is exploring a sale and has attracted interest from Johnson & Johnson and Novartis AG, Bloomberg reported. Pharmacyclics could fetch $17 billion-$18 billion from a possible sale, Bloomberg said on Wednesday, citing people familiar with the matter.

    Comment?

  8. J&J ordered by jury to pay $2.5 million over antipsychotic drugRead the original story w/Photo

    Tuesday Feb 24 | The Verona-Cedar Grove Times

    A jury ordered Johnson & Johnson to pay $2.5 million to the family of an autistic man who developed female breasts while taking the company's Risperdal antipsychotic drug, in the first verdict in thousands of lawsuits filed over the medication's side effect.

    Comment?

  9. We Are Not Surprised That J&J May Be Selling Off CordisRead the original story w/Photo

    Tuesday Feb 24 | Forbes.com

    Great Speculations' contributor page is devoted to investing ideas that will help make you wiser and richer. Most articles will contain actionable advice.

    Comment?

  10. Mondelez Names Marques EVP and President for North AmericaRead the original story w/Photo

    Tuesday Feb 24 | CSP

    Mondelez International, a leading maker of biscuits, chocolate, gum and candy, has announced that Roberto Marques, 49, will join the company in mid-March and become executive vice president and president for North America. Marques succeeds Mark Clouse, who became the company's Chief Growth Officer in July 2014.In this role, he will be responsible for leading the company's $7 billion business in the United States and Canada, which includes Oreo and belVita biscuits, Triscuit and Wheat Thins crackers, Halls candy and Trident gum.

    Comment?

  11. Westport bets on Milpitas with $45M campus buy from J&JRead the original story

    Tuesday Feb 24 | Business Journal

    With its $45.25 million purchase of a vacant, 400,000-square-foot office park near the Great Mall, Westport Capital Partners LLC is betting that Milpitas is in line to land new and expanding tech tenants. "We think we can take it and make it a very modern, R&D office opportunity for tenants in today's marketplace," Eric Clapp , managing director for Westport Capital Partners, said in a phone call.

    Comment?

  12. If Oscar Ads Had Categories, These Brands Would be the WinnersRead the original story w/Photo

    Tuesday Feb 24 | Forbes.com

    I'm Chairman, North America of Landor Associates, a brand consulting and design firm that specializes in creating agile brands that thrive in today's disruptive, changing market. I work with some of the most powerful brands in the world, and oversee Landor's new business efforts in North America.

    Comment?

  13. Asco-GU Preview: First-Line Prostate Cancer Chemo Not Dead YetRead the original story w/Photo

    Tuesday Feb 24 | Seeking Alpha

    Patients with the AR-V7 mutation, who make up about 10% of the treatment-naive population, should "probably be offered chemo", Dr Emmanuel Antonarakis will argue at Asco's Genitourinary Cancers Symposium, which gets under way on Thursday. Of course his work is extremely early, but will nevertheless be of interest to followers of Sanofi and Tokai Pharmaceuticals .

    Comment?

  14. Legal-Bay Lawsuit Settlement Funding to Increase Funding Amounts on...Read the original story

    Tuesday Feb 24 | Sys-Con Media

    Regardless of an ultimate resolution of the entire case litigation, Legal-Bay is announcing an increase in funding amounts on Pinnacle hip pre-settlement funding requests. According to Legal-Bay's sources close to the litigation, J&J has been unwilling to discuss settlement figures regarding the Pinnacle hip due to their belief that the Pinnacle hip has shown positive reports regarding the rate of defaults.

    Comment?

  15. J&J settles more defective hip device lawsuitsRead the original story w/Photo

    Monday Feb 23 | West Australian

    Johnson & Johnson has reached an agreement to settle some 1,400 claims over defective hip replacement devices, a spokeswoman for the health care giant said Monday. The agreement extends the benefits of a 2013 settlement with plaintiffs involving about 8,000 cases over ASR Hip System devices that cost the company $2.5 billion.

    Comment?

  16. Johnson & Johnson: Down 10% Since Earnings, This Slow-And-Steady Dividend Gem Is A StealRead the original story w/Photo

    Monday Feb 23 | Seeking Alpha

    J&J reported disappointing numbers, but currency and divestitures were the causes. Excluding these transitory effects reveals a different picture, which is that underlying growth is actually quite strong.

    Comment?

  17. J&J to Pay As Much As $420 Million More in ASR Hip AccordRead the original story w/Photo

    Monday Feb 23 | San Diego Source

    Johnson & Johnson agreed to pay as much as $420 million more to resolve lawsuits over its ASR hip implants that were excluded from a $2.5 billion settlement in 2013 of claims that the recalled devices were defective and caused metal poisoning in patients.

    Comment?

  18. There Are Crazy Valuations, and Then There Are the Valuations of These 3 StocksRead the original story w/Photo

    Sunday Feb 22 | The Motley Fool

    However, some stocks have sky-high valuations that we can't figure out. Our analysts here discuss three examples and explain why their high valuations don't make a ton of sense.

    Comment?

  19. Edward W. Weintraut, 86, watch repairman for six decadesRead the original story w/Photo

    Saturday Feb 21 | Philly.com

    "It's sort of in the blood," Edward W. Weintraut said in a 2013 Inquirer interview, explaining why he had been repairing watches at his Center City shop since 1957. "I'm needed."

    Comment?

  20. Pennsauken-based Super Pretzel brings snacking back to basicsRead the original story w/Photo

    Saturday Feb 21 | The Jersey Journal

    With social media websites such as Pinterest and Facebook displaying crazy snack ideas like turning fruits and vegetables into edible art, some moms may feel the pressure of needing to please their children with creative cuisine. SuperPretzel soft pretzels - wholesome snacks that are fun, filling and nutritious - are hoping to bring snack time back to basics.

    Comment?